Posts by Mourabit Halima

As the efficacy of CAR-T therapy in B-cell lymphoma becomes increasingly recognized, some studies have focused on its application in treating refractory/relapsed central nervous system (CNS) B-cell lymphoma. Refractory/relapsed CNS B-cell lymphoma patients were initially excluded from early CAR-T clinical trials, but as CAR-T therapy's real-world application grows, these patients can achieve optimistic outcomes. However, patients with high tumor burden face a high incidence of immune effector cell-associated neurotoxicity syndrome (ICANS) and poor outcomes. There is an urgent need for an effective bridging therapy to reduce ICANS incidence and improve remission rates in multidrug-resistant CNS-involved patients. From June 13-16, 2024, at the 29th European Hematology Association (EHA) Annual Meeting, Dr.  Hui Shi from Professors Xiaoyan Ke and Kai Hu's team at Beijing Gaobo Hospital will present a report titled "INCORPORATING RADIATION WITH CAR T-CELL THERAPY DEMONSTRATED A HIGH RATE OF REMISSION IN PATIENTS WITH B CELL LYMPHOMA INVOLVING THE CNS," offering new insights for treating refractory/relapsed multidrug-resistant CNS B-cell lymphoma patients.

Multiple myeloma (MM) is the second most common hematologic malignancy and is a disease of terminally differentiated plasma cells. As MM progresses, treatment becomes increasingly difficult, and the periods of remission after each relapse grow shorter. There is an urgent need for new therapeutic combinations that can provide deeper and more durable responses. Recently, Haematologica published the final results of the phase I/IIa ANCHOR study, which investigated the efficacy and safety of the novel alkylating peptide-drug conjugate melflufen flufenamide (melflufen) in combination with dexamethasone and either daratumumab or bortezomib for the treatment of relapsed/refractory MM.

Hemophilia B is characterized by a deficiency in clotting factor IX due to mutations in the F9 gene, impairing coagulation and increasing bleeding risk. Predominantly affecting males, hemophilia B can be classified as mild (factor IX activity >5% and <40% of normal levels), moderate (1%-5%), or severe (<1%). The primary clinical manifestation is bleeding, most commonly musculoskeletal bleeding, which can lead to severe joint disease and significantly impact the quality of life.

For chronic myeloid leukemia (CML) patients who achieve deep and durable molecular remission, the feasibility of discontinuing tyrosine kinase inhibitors (TKIs) has been established, challenging the notion of lifelong dependency on TKIs. Achieving treatment-free remission (TFR) without affecting overall survival (OS) is a key objective in current CML treatment. Recently, the Journal of Clinical Oncology (JCO) published the three-year follow-up results of the EURO-SKI study, providing a final analysis of prognostic factors related to TFR. Here, we present a summary of the findings from this comprehensive study.

With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case analyses, and scientific experience exchanges, covering various subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, indolent lymphoma, extranodal lymphoma, plasma cell myeloma, and more. Core topics focused on the application of high-tech, optimization strategies for radiation therapy, new treatment methods, precise classification, and diagnostic techniques, providing participants with valuable insights into the latest advancements and future trends in the field. Notably, the conference brought together many internationally renowned experts who provided in-depth analyses and interpretations of lymphoma guidelines, evidence-based medicine, and clinical practice, offering excellent academic references. Professor Shunan Qi from the Cancer Hospital of the Chinese Academy of Medical Sciences, representing the organizing unit of this conference, gave an exclusive interview to "Oncology Frontier - Hematology Frontier" to provide a detailed interpretation of the conference's exciting content and advancements.